OFFICAL PROJECT SITE
Novel Target for Treatment of Chronic Inflammatory Diseases — Notid
Kallelse till extra bolagsstämma
Pressmeddelande: Umeå, 17 August 2020. Kallelse till extra bolagsstämma Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till extra bolagsstämma fredagen den 28 augusti 2020, kl. 12:00 på Tvistevägen 48C i Umeå. Förslag till dagordning och beslut bifogas. Handlingar enligt aktiebolagslagen (2005:551) skickas ut på begäran. Aktieägare som [...]
Growing up with Juvenile Idiopathic Arthritis
Clara Laurell. Foto: Roger Larsson, Hallandsposten News: Umeå, 27 August 2020. Growing up with Juvenile Idiopathic Arthritis Every year, more than 200 Swedish children are diagnosed with Juvenile Idiopathic Arthritis (JIA), also called childhood rheumatism. JIA is a rheumatic disease that affects joints, causes severe pain and reduce the quality [...]
The founders want to improve patients’ quality of life
Lipum is on a steady course towards clinical studies with its candidate for the treatment of juvenile idiopathic arthritis (SOL116). Previous we announced that the cell line was fully developed and was ready for the next step. BioStock has taken the opportunity to talk to one of our founders, Professor [...]
Capital raise secures development of Lipum’s novel drug
Press release June 25, 2020 Lipum is supported by Horizon 2020, the EU framework program for research and development, and was granted 23 MSEK for the development of a biological pharmaceutical for treatment of chronic inflammatory diseases. In addition to this grant another 25 MSEK was raised in 2019. Now [...]
Lipum kallar till årsstämma
Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till årsstämma torsdagen den 25 juni 2020, kl. 16:00 på Tvistevägen 48C i Umeå. Aktieägare som önskar delta i stämman ska vara införd i aktieboken per dagen för stämman. Föranmälan senast måndagen den 22 juni 2019 per e-post till investor@lipum.se/sv. [...]
Another step towards a novel treatment
What effect has elevated levels of our target molecule on human blood? Together with our partner Immuneed we will increase our understanding. Another step towards a novel treatment of inflammatory diseases.
Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741
Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases
Project budget:
3.2 M€
Funding from the EU:
2.2 M€
Start:
2018-11-01
End:
2020-07-31